EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy

Jim Middelburg, Gaby Schaap, Marjolein Sluijter, Katy Lloyd, Vitalijs Ovcinnikovs, Janine Schuurman, Sjoerd H van der Burg, Kristel Kemper, Thorbald van Hall

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Jim Middelburg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Bispecific, CD3 Complex, Cancer Vaccines, Melanoma, Experimental. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genmab.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD3 bispecific antibody (CD3 bsAb) therapy has become an established treatment modality for some cancer types and exploits endogenous T cells irrespective of their specificity. However, durable clinical responses are hampered by immune escape through loss of tumor target antigen expression. Induction of long-lasting tumor-specific immunity might therefore improve therapeutic efficacy, but has not been studied in detail yet for CD3 bsAbs. Here, we examined multiple combination strategies aiming to improve survival rates in solid tumors and, simultaneously, install endogenous immunity capable of protection to tumor rechallenge.

Methods

Two syngeneic mouse tumor models were employed: The immunologically “cold” B16F10 melanoma and the immunologically “hot” MC38.TRP1 colon carcinoma model. Mice were treated with CD3xTRP1 bsAb (murine Fc-inert immunoglobulin G2a) as monotherapy, or in combination with agonistic costimulatory antibodies, Fc-active tumor-opsonizing antibodies, or tumor-(non)specific vaccines. Treatment efficacy of primary tumors and protection from rechallenge was monitored, as well as induction of tumor-specific T-cell responses.

Results

In the immunologically “cold” B16F10 model, all combination therapies improved antitumor activity compared with CD3 bsAb monotherapy and induced systemic tumor-specific T-cell responses. However, this endogenous T-cell immunity swiftly waned and failed to protect mice from subsequent tumor rechallenge, except for combination therapy with tumor-specific vaccination. These vaccines strongly improved the therapeutic efficacy of CD3 bsAb against primary tumors and led to long-term immunological protection. In the immunologically “hot” MC38.TRP1 model, CD3 bsAb combined with only the vaccine adjuvant was sufficient to generate protective T-cell immunity and, moreover, prevented tumor escape via antigen loss.

Conclusions

These results demonstrate the impact of tumor antigenicity on the induction of protective endogenous antitumor immunity during CD3 bsAb treatment and, importantly, show that the combination with tumor-specific vaccines improves therapeutic efficacy and installs long-term immunological memory in both “hot” and “cold” tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificCD3 ComplexCancer VaccinesMelanoma, ExperimentalAnimalsMiceCell Line, TumorMice, Inbred C57BLFemaleHumansDisease Models, AnimalImmunotherapy

Stichwörter der Autor:innen

Bispecific T cell engager - BiTECombination therapyImmunotherapyMemoryVaccine

Substanzen

Antibodies, BispecificCD3 ComplexCancer Vaccines

Autor:innen und Institutionen

  • Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
  • Genmab BV, Utrecht, Utrecht, The Netherlands.
  • Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands T.van_Hall@lumc.nl.

Förderung

  • Genmab

Zitieren

APA

Middelburg, J., Schaap, G., Sluijter, M., Lloyd, K., Ovcinnikovs, V., Schuurman, J., van der Burg, S. H., Kemper, K., & van Hall, T. (2025). Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010331

Vancouver

Middelburg J, Schaap G, Sluijter M, Lloyd K, Ovcinnikovs V, Schuurman J, et al. Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010331

BibTeX
@article{Middelburg2025,
  author = {Middelburg, Jim and Schaap, Gaby and Sluijter, Marjolein and Lloyd, Katy and Ovcinnikovs, Vitalijs and Schuurman, Janine and van der Burg, Sjoerd H and Kemper, Kristel and van Hall, Thorbald},
  title = {Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010331}
}
Kostenlos starten →